HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Conjugated (USP) Estrogens (Premarin)

Subscribe to New Research on Conjugated (USP) Estrogens

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Also Known As:

Premarin; Conjugated Estrogens; Estrogens, Conjugated; Estrogens, Conjugated (USP); ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Carentil; Climarest; Climopax; Congest; Conjugated Equine Estrogens; Dagynil; Estro-Feminal; Estrogenic Hormones, Conjugated; Femavit; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Oestro-Feminal; Oestrofeminal; Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); Prelestrin; Presomen; Progens; Solvay Brand of Estrogens, Conjugated; Transannon; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Conjugated Estrogenic Hormones; Conjugated Estrogenic Substances; Equine Estrogens, Conjugated; Estrogenic Substances, Conjugated

Networked: 469 relevant articles (34 outcomes, 111 trials/studies)

Relationship Network

Drug Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 60571
  - Gonadal Hormones: 363
    - Gonadal Steroid Hormones: 3173
      - Estradiol Congeners: 117
        Conjugated (USP) Estrogens: 469
        Prempro: 8
        CAMFTP protocol
        formatrix
        Ovaribran
        Premaril Plus
        Seda-Presomen

Experts

1.	Pickar, James H: 13 articles (09/2015 - 05/2002)
2.	Komm, Barry S: 11 articles (09/2015 - 12/2008)
3.	Chlebowski, Rowan T: 9 articles (01/2014 - 06/2003)
4.	Stefanick, Marcia L: 9 articles (02/2009 - 12/2002)
5.	Hendrix, Susan L: 8 articles (10/2009 - 06/2003)
6.	Mirkin, Sebastian: 7 articles (03/2015 - 03/2010)
7.	Manson, Joann E: 7 articles (04/2014 - 02/2006)
8.	Prentice, Ross L: 7 articles (03/2014 - 01/2008)
9.	Kuller, Lewis H: 7 articles (01/2014 - 07/2006)
10.	Lane, Dorothy S: 7 articles (01/2014 - 06/2004)

Related Diseases

1.	Osteoporosis 01/01/2010 - "Combination therapy using BZA and conjugated estrogens (CE) is currently in late stage development representing a new paradigm for the treatment of menopausal symptoms and prevention of osteoporosis. " 01/01/1982 - "Premarin (20 mg/kg q.d.) failed to prevent steroid accelerated osteoporosis." 01/01/2004 - "The Women's Health, Osteoporosis, Progestin, Estrogen study concluded that lower doses of conjugated estrogens (0.3 mg) are just as effective in treating postmenopausal symptoms as higher doses (0.625 mg) and result in fewer side effects. " 07/01/1986 - "In view of the hormonal and biochemical changes after Premarin therapy, it is concluded that estrogen (Premarin) replacement should be effective in the treatment of enhanced bone loss or osteoporosis in postmenopausal women. " 07/01/2014 - "Describe the effects of conjugated estrogens/bazedoxifene (CE/BZA), a new treatment for vasomotor symptoms (VMS) and osteoporosis prevention, on menopause-specific quality of life (MSQOL) across different patient population types in phase 3 clinical trials. "
2.	Hyperplasia 05/01/1980 - " In terms of prevention, a study showed that low-dose cyclical Premarin (.625 mg) resulted in an incidence of hyperplasia of 7% and with higher doses (1.25 mg) rose to 15%. " 09/01/1989 - "Hyperplasia developed in 30 and 57% of the patients who received the above conjugated equine estrogens and placebo regimens, respectively. " 09/01/1989 - "At 1 year, therapy with 0.625 mg conjugated equine estrogens or 1.25 mg conjugated equine estrogens for 25 days of a 30-day cycle and 5 mg medroxyprogesterone acetate added to the last 11 days of the conjugated equine estrogens cycle was associated with hyperplasia in 0 and 10% of the patients, respectively (P = not significant). " 04/01/1998 - "Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys." 03/01/1982 - "Premarin was effective in terminating endometrial bleeding in patients with biopsy-proved pathology consisting of secretory, proliferative, menstrual, polypoid, or cystic hyperplasia, as well as endometritis."
3.	Vaginitis 08/01/1994 - "Relief from atrophic vaginitis can be achieved with 0.3 mg of conjugated estrogens administered vaginally three times per week. " 04/01/1977 - "The relief of atrophic vaginitis by premarin did not result in an improvement in libido and this suggests that the ability and the desire to have sexual intercourse are not related. " 07/01/2009 - "The aim of this study was to evaluate the efficacy and safety of low-dose conjugated estrogens (CE) cream for treatment of atrophic vaginitis. " 11/01/2010 - "In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). " 09/01/2004 - "Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women."
4.	Uremia 10/01/2000 - "Conjugated estrogens shorten the prolonged bleeding time in uremic patients and are similarly effective in a rat model of uremia. " 10/01/1991 - "We have reported previously that conjugated estrogens that are effective in shortening the prolonged bleeding time in uremic patients are also effective on bleeding time in a rat model of uremia. " 01/01/1990 - "We have reported previously that a mixture of conjugated estrogens which is effective in shortening the prolonged bleeding time in uremic patients is also effective on bleeding time in a rat model of uremia. " 07/01/1990 - "Intravenous conjugated estrogens reduce the prolonged bleeding time in uremic patients and in a rat model of uremia. " 12/01/1988 - "The studies so far available indicate that repeated estrogen administrations are necessary to short bleeding time in uremia in a dose range of 95 to 325 mg. With the present study we wanted to establish whether single or repeated doses are required to induce a significant shortening of bleeding time in uremia, and the minimum cumulative dose of conjugated estrogens necessary to control bleeding time for a prolonged period of time, and to check whether the prolonged effect of estrogens on bleeding time in uremia is due to an accumulation of the drug or its metabolites in the blood. "
5.	Breast Neoplasms (Breast Cancer) 10/01/2013 - "These results may be of clinical relevance since in the combined WHI trial an increased breast cancer risk was found during treatment with conjugated equine estrogens plus MPA." 11/15/2008 - "Re: "Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study"." 06/15/2008 - "Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study." 12/15/1991 - "The results of this large study provide no evidence that the use of unopposed conjugated estrogens increases the risk of breast cancer, even after long durations of use or long latent intervals, but the possibility of a modest increase (less than a doubling) could not be excluded. " 07/01/2014 - "Later reports from the WHI indicated that a MHT regimen with conjugated equine estrogens alone decreased the risk of breast cancer by 23%. "

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	Conjugated (USP) Estrogens (Premarin)
3.	Medroxyprogesterone Acetate (Depo-Provera)
4.	bazedoxifene acetate
5.	tibolone
6.	Hormones
7.	Estradiol (Estrace)
8.	Tablets
9.	Progestins (Progestagens)
10.	Raloxifene (Evista)

Related Therapies and Procedures

1.	Oral Administration
2.	Ovariectomy (Oophorectomy)
3.	Drug Therapy (Chemotherapy)
4.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
5.	Estrogen Replacement Therapy